Molecular remission rate in the PB and BM with VEN, LEN, and rituximab in R/R MCL
. | 3 months . | 6 months . | 9 months . | 12 months . | ||||
---|---|---|---|---|---|---|---|---|
BM . | PB . | BM . | PB . | BM . | PB . | BM . | PB . | |
Negative | 36 | 28 | 33 | 39 | 11 | 31 | 10 | 24 |
Positive | 1 | 0 | 2 | 0 | 5 | 1 | 1 | 2 |
Not evaluable | 22 | 31 | 24 | 20 | 43 | 27 | 48 | 33 |
Molecular remission in evaluable patients (%) | 97 | 100 | 94 | 100 | 69 | 97 | 91 | 92 |
Molecular remission, intention to treat (%) | 61 | 47 | 56 | 66 | 19 | 53 | 17 | 41 |
. | 3 months . | 6 months . | 9 months . | 12 months . | ||||
---|---|---|---|---|---|---|---|---|
BM . | PB . | BM . | PB . | BM . | PB . | BM . | PB . | |
Negative | 36 | 28 | 33 | 39 | 11 | 31 | 10 | 24 |
Positive | 1 | 0 | 2 | 0 | 5 | 1 | 1 | 2 |
Not evaluable | 22 | 31 | 24 | 20 | 43 | 27 | 48 | 33 |
Molecular remission in evaluable patients (%) | 97 | 100 | 94 | 100 | 69 | 97 | 91 | 92 |
Molecular remission, intention to treat (%) | 61 | 47 | 56 | 66 | 19 | 53 | 17 | 41 |